Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,041,900
  • Shares Outstanding, K 144,001
  • Annual Sales, $ 10,982 M
  • Annual Income, $ 1,556 M
  • 60-Month Beta 0.20
  • Price/Sales 3.96
  • Price/Cash Flow 11.11
  • Price/Book 3.40
Trade BIIB with:

Options Overview Details

View History
  • Implied Volatility 29.31% ( -2.19%)
  • Historical Volatility 27.50%
  • IV Percentile 0%
  • IV Rank 0.19%
  • IV High 99.07% on 09/16/22
  • IV Low 29.18% on 08/02/22
  • Put/Call Vol Ratio 1.18
  • Today's Volume 10,513
  • Volume Avg (30-Day) 7,569
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 169,101
  • Open Int (30-Day) 162,519

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 3.41
  • Number of Estimates 25
  • High Estimate 3.89
  • Low Estimate 2.79
  • Prior Year 3.39
  • Growth Rate Est. (year over year) +0.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
274.63 +8.84%
on 11/03/22
311.88 -4.16%
on 11/30/22
+20.53 (+7.38%)
since 11/02/22
3-Month
194.42 +53.74%
on 09/06/22
311.88 -4.16%
on 11/30/22
+102.87 (+52.48%)
since 09/02/22
52-Week
187.16 +59.70%
on 05/09/22
311.88 -4.16%
on 11/30/22
+70.38 (+30.80%)
since 12/02/21

Most Recent Stories

More News
3 Stocks You'll Regret Not Buying This Year

With slowing inflation, indications of slower rate hikes by the Fed beginning this month, and resilient employment growth, fundamentally strong stocks Biogen (BIIB), APA Corporation (APA), and Nathan’s...

APA : 47.11 (+0.83%)
BIIB : 298.90 (-0.98%)
NATH : 67.96 (+1.98%)
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal

Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.

AZN : 68.47 (+0.19%)
BIIB : 298.90 (-0.98%)
PFE : 50.91 (-0.33%)
LLY : 374.76 (+1.20%)
ROIV : 6.30 (+8.62%)
Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug

Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six...

BIIB : 298.90 (-0.98%)
RHHBY : 41.0800 (-0.15%)
LLY : 374.76 (+1.20%)
VRTX : 321.37 (+0.19%)
Biogen, Wayfair rise; CrowdStrike, NetApp fall

Stocks that traded heavily or had substantial price changes Wednesday: Biogen, Wayfair rise; CrowdStrike, NetApp fall

INTU : 407.92 (-1.96%)
WDAY : 170.99 (+0.89%)
BIIB : 298.90 (-0.98%)
W : 42.10 (+1.13%)
CRWD : 124.00 (-0.06%)
Stock Investors Await Fed Chair Powell’s Speech

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.30%. ...

$SPX : 4,071.70 (-0.12%)
SPY : 406.91 (-0.12%)
$DOWI : 34,429.88 (+0.10%)
DIA : 344.74 (+0.10%)
$IUXX : 11,994.26 (-0.40%)
QQQ : 292.55 (-0.40%)
^BTCUSD : 17,020.90 (+0.06%)
NTAP : 66.43 (-2.41%)
HRL : 47.64 (+0.11%)
MTB : 169.10 (+0.46%)
COF : 97.69 (-1.64%)
JPM : 135.16 (-0.79%)
Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects

Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse...

BIIB : 298.90 (-0.98%)
RHHBY : 41.0800 (-0.15%)
LLY : 374.76 (+1.20%)
VRTX : 321.37 (+0.19%)
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion

Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.

GSK : 35.35 (+0.91%)
BIIB : 298.90 (-0.98%)
GILD : 89.03 (+1.29%)
SLDB : 6.77 (+1.80%)
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

BIIB : 298.90 (-0.98%)
ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

BIIB : 298.90 (-0.98%)
Biogen (BIIB) Down on Report of Death in Alzheimer's Study

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.

BIIB : 298.90 (-0.98%)
RHHBY : 41.0800 (-0.15%)
LLY : 374.76 (+1.20%)
PRTA : 65.00 (+6.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 310.66
2nd Resistance Point 307.86
1st Resistance Point 303.38
Last Price 298.90
1st Support Level 296.10
2nd Support Level 293.30
3rd Support Level 288.82

See More

52-Week High 311.88
Last Price 298.90
Fibonacci 61.8% 264.24
Fibonacci 50% 249.52
Fibonacci 38.2% 234.80
52-Week Low 187.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar